Bioperfectus sets out for post-pandemic daily surveillance: COVID-19 Antigen Rapid Test included in the EU Common List

Company news
2021-07-19

We Bioperfectus are glad to announce that our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit has been included in the EU Health Security Committee common list of COVID-19 rapid antigen tests.

 

The detection capacity of Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit for the SARS-CoV-2 mutation lineages (B.1.1.7, B.1.351, B.1.617.1 and P.1) has also been validated. Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit can detect SARS-CoV-2 within 15 minutes and compatible with specimens of nasal swab, nasopharyngeal swab and oropharyngeal swab. With package of 1, 2, 5, 10, 15, 20, 25, 50 Tests/Kit, our kits provide flexible options to fulfill different clinical throughput requirements.

 

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14